David is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he co-founded in 2006, David oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a Nasdaq-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, David served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. David began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He received a BSc in pharmacy and an MBA from the University of British Columbia.
Management team
Scientific Advisor
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Board Of Directors
Scientific Advisory Board
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
